Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01625351
Other study ID # RADIANT
Secondary ID NCI-2012-00588
Status Completed
Phase Phase 1
First received
Last updated
Start date August 20, 2012
Est. completion date February 10, 2020

Study information

Verified date October 2020
Source St. Jude Children's Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I study designed to determine the feasibility of transplantation using a novel transplant approach that employs a two-stage haploidentical cell infusion following myeloablative conditioning. This strategy, which includes selective depletion of naïve T cells, may speed immune reconstitution thereby potentially reducing the limitations of traditional haploidentical hematopoietic stem cell transplantation (HSCT) and increasing its potential therapeutic application. Additionally, the investigators intend to explore overall survival, event-free survival, hematopoietic cell recovery and engraftment as well as infection rates and complications in these patients.


Description:

Twelve participants and 12 donors will be enrolled on this study. Donors will undergo seven days of hematopoietic stem cell (HSC) mobilization followed by two apheresis collections. Each apheresis collection will be processed by the CliniMACS system. DONORS: A mobilization regimen of granulocyte colony stimulating factor (G-CSF) will be used to obtain a peripheral blood stem cell (PBSC) product from the donor. Apheresis will be performed for a minimum of two consecutive days, including one day for each cell product delivered. STUDY PARTICIPANTS: Participants will undergo a two-stage haploidentical cell infusion following myeloablative conditioning. The first cell infusion will be a CD3-depleted product and the second infusion will be a CD45RA-depleted product. Primary Objective: - To determine the feasibility of haploidentical HSCT using two infusions engineered by negative selection on the Miltenyi CliniMACS system- the first by selective depletion of CD3+ cells, followed by a second depleted of CD45RA+ cells, in children with relapsed or refractory solid tumors or lymphomas. Secondary Objectives: - To estimate hematopoietic cell recovery and engraftment rates for the patients. - To estimate infection rates and complications. - To estimate the one-year overall survival (OS) and event-free survival (EFS) for the study patients.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date February 10, 2020
Est. primary completion date February 10, 2020
Accepts healthy volunteers No
Gender All
Age group 2 Years to 21 Years
Eligibility Inclusion Criteria - Transplant Recipients: - At least 2 years of age and less than or equal to 21 years of age. - Histologically confirmed solid tumor or lymphoma at original diagnosis: - Ewing Sarcoma Family of Tumors (ESFT) - Gastrointestinal tumors - Germ Cell tumors - Hepatic tumors (including hepatocellular carcinoma and hepatoblastoma) - Lymphoma (including Hodgkin and non-Hodgkin lymphoma) - Kidney tumors (including Wilms tumor, rhabdoid tumors, clear cell carcinoma, and renal cell carcinoma) - Melanoma - Neuroblastoma - Soft tissue sarcoma (including rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma) - Malignancy has no reasonable expectation of cure with available alternative salvage therapy. - Has a suitable human leukocyte antigen (HLA) haploidentical donor available. - At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy. - Has recovered from all acute NCI Common Toxicity Criteria grade II-IV acute non-hematologic toxicities from prior therapy per the judgment of the PI. - Shortening fraction greater than or equal to 25%. - Creatinine clearance or glomerular filtration rate (GFR) greater than or equal to 50 mL/min/1.73 m2. - Pulse oximetry greater than or equal to 92% on room air - Alanine aminotransferase (ALT) and aspartate transaminase (AST) less than or equal to3 times the upper limit of the institution-established normal range. - Direct bilirubin less than or equal to 3.0 mg/dL. - Karnofsky or Lansky performance score of greater than or equal to 50. Exclusion Criteria - Transplant Recipients: - Newly diagnosed patients with no prior attempt at curative therapy. - Any primary or active central nervous system (CNS) malignancy, including metastatic disease. - Any active or prior malignant or pre-malignant condition of the bone marrow, excluding metastasis of the primary malignancy. - Prior allogeneic hematopoietic stem cell transplant. - Prior autologous stem cell transplant within previous 3 months. - Allergy to murine products or positive human anti-mouse antibody (HAMA). - (Female only) Known pregnancy (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment). - (Female only) Breast feeding. Inclusion Criteria - Donors: - At least 18 years of age. - Partially HLA matched family member. - Human immunodeficiency virus (HIV) negative. Exclusion Criteria - Donors: - (Female only) Known pregnancy (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment). - (Female only) Breast feeding.

Study Design


Intervention

Drug:
alemtuzumab
Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
fludarabine
Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
sirolimus
Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.) Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.
Busulfan
Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
melphalan
Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
Biological:
stem cells
Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
Device:
CliniMACS
The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Locations

Country Name City State
United States St. Jude Children's Research Hospital Memphis Tennessee

Sponsors (2)

Lead Sponsor Collaborator
St. Jude Children's Research Hospital CURE Childhood Cancer, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of haploidentical HSCT Feasibility is defined as engraftment (ANC= 500/mm3 for 3 consecutive tests performed on different days) evaluated before day +30. 30 days post transplantation
Secondary hematopoietic cell recovery and engraftment rates They will be reported and presented descriptively. Specifically, the hematopoietic cell recovery and engraftment rates will be reported with a Blyth-Still-Casella 95% confidence interval. 30 days post transplantation
Secondary infection rates and complications The proportion of patients who develop infections and complications will be estimated and a Blyth-Still-Casella 95% confidence interval will be provided. up to 5 years
Secondary overall survival (OS) Defined based on any death. The Kaplan-Meier Estimate will be provided. up to 1 year after transplantation
Secondary event-free survival The Kaplan-Meier Estimate will be provided. up to 1 year after transplantation
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1